1887
Volume 2007, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

About 30 years ago bone marrow transplantation was an experimental procedure carried out as a last resort in terminally ill patients. Nowadays hematopoietic stem cell transplantation (HSCT) has become a standard procedure for many severe malignant or non-malignant disorders of the hematopoietic system. It is well known that HSCT is associated with transplant related mortality and morbidity (TRM), the risk of which in allogeneic transplantations can reach 40%; in contrast the risk is less than 5% in autologous transplantation. However; HSCT outcome has been improved significantly over the past decade both in terms of reduced TRM and reduced risk of relapse of the original disease.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2007.2.7
2007-11-01
2019-10-21
Loading full text...

Full text loading...

References

  1. 1. Spangrude   GJ. . Biological and clinical aspects of hemopoietic stem cells. . Ann Rev Med . 1994; ;45: : 93– 104 .
    [Google Scholar]
  2. 2. Thomas   ED., , Lochte   HL Jr., , Cannon   JH., , Sahler   OD., , Ferrebee   JW. . Supralethal whole body irradiation and isologous marrow transplantation in man. . J Clin Invest . 1959; ;38: : 1709– 1716 .
    [Google Scholar]
  3. 3. Thomas   ED., , Buckner   CD., , Banaji   M. , et al. , One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. . Blood . 1977; ;49: : 511– 533 .
    [Google Scholar]
  4. 4. Gratwohl   A., , Hermans   J., , Baldomero   H. , et al. , Indications for hemopoietic precursor cell transplants in Europe. . J Hematol . 1996; ;92: : 35– 43 .
    [Google Scholar]
  5. 5. Goldman   JM., , Schmitz   N., , Niethammer   D., , Gratwohl   A. . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe in Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. . Bone Marrow Transplant . 1998; ;21: 1 : 1– 7 .
    [Google Scholar]
  6. 6. Slavin   S., , Nagler   A., , Naparstek   E., , Kapelushnik   Y., , Aker   M., , Cividalli   G. , et al. , Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. . Blood . 1998; ;91: : 756– 763 .
    [Google Scholar]
  7. 7. Thomas   DD. . Bone marrow transplantation. . A review. Semin Hematol . 1999; ;36: Suppl 7 : 95– 103 .
    [Google Scholar]
  8. 8. Goldschmidt   H., , Hegenbart   U., , Haas   R., , Hunstein   W. . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7g/m2) and granulocyte colonystimulating factor in patients with multiple myeloma. . Bone Marrow Transplant . 1996; ;17: : 691– 697 .
    [Google Scholar]
  9. 9. Comenzo   RL., , Malachowski   ME., , Miller   KB. , et al. , Engraftment with peripheral blood stem cells collected by large volume leucopheresis for patients with lymphoma. . Transfusion . 1992; ;32: : 729– 731 .
    [Google Scholar]
  10. 10. Rubinstein   R., , Dobrila   L., , Rosenfield   RE. , et al. , Processing and cryopreservativation of placenta/umbilical cord blood for unrelated bone marrow reconstitution. . Proc Natl Acad Sci USA . 1995; ;92: : 10119– 10122 .
    [Google Scholar]
  11. 11. Gluckman   E., , Rocha   V., , Chastang   C. . Cord blood stem cell transplantation. . Bailliere's Clin Hematol . 1999; ;12: : 279– 292 .
    [Google Scholar]
  12. 12. Gluckman   E. . Current status of UCB/HSCT. . Exp Hematol . 2000; ;28: : 1197– 1205 .
    [Google Scholar]
  13. 13. Barker   JN., , Weisdorf   DJ., , DeFor   TE. , et al. , Transplantation of partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. . Blood . 2005; ;105: : 1343– 1347 .
    [Google Scholar]
  14. 14. Lemoli   RM., , Curti   A., , Tura   S. . Negative Selection of autologous peripheral blood stem cells. . Baillier's Clin Hematol . 1999; ;12: : 57– 69 .
    [Google Scholar]
  15. 15. Appelbaum   FR. . HSCT as immunotherapy. . Nature . 2001; ;411: : 385– 389 .
    [Google Scholar]
  16. 16. Kottaridis   PD., , Milligan   DW., , Chopra   R. . In vivo CAMPATH-1H prevents graft versus host disease following nonmyeloablative stem cell transplantation. . Blood . 2000; ;96: : 2419– 2425 .
    [Google Scholar]
  17. 17. Lee   JH., , Choi   SJ., , Kim   S. , et al. , GVHD specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic HSCT. . Br J Hematol . 2003; ;122: : 637– 644 .
    [Google Scholar]
  18. 18. Miller   KB., , Schenkein   DP., , Comenzo   RL. , et al. , Adjusted dose continuous infusion cyclosporine A to prevent GVHD following allogeneic bone marrow transplantation. . Ann Hematol . 1994; ;68: : 15– 20 .
    [Google Scholar]
  19. 19. Goulmy   E. . Human Minor histocompatibility antigens; new concepts for marrow transplantation and adoptive immunotherapy. . Imm Rec . 1997; ;157: : 125– 140 .
    [Google Scholar]
  20. 20. Sasazuki   T., , Juji   T., , Morishiema   Y. , et al. , Effect of matching of class 1 HLA alleles on Clinical outcome after transplantation of haemopoietic stem cells for an unrelated donor. . N Engl J Med . 1998; ;1339: : 1177– 1185 .
    [Google Scholar]
  21. 21. Hows   J., , Bradley   B. . Transplantation for patients without HLA identical siblings. . In: Brenner   MK., Hojfbrand   AV. , eds. Recent advances in haematology . Vol 8 . London: : Churchill Livingstone;   1996; ; : 191– 212 .
    [Google Scholar]
  22. 22. Khouri   IF., , Kealing   M. . Transplant-lite: Induction of graftversus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. . J CO . 1998; ;16: : 2817– 2824 .
    [Google Scholar]
  23. 23. MacKinnon   S. . Who may benefit from donor leucocyte infusions after allogeneic SCT?.   Br J Hematol . 2000; ;110: : 12– 17 .
    [Google Scholar]
  24. 24. Cullis   JO., , Jiang   YZ., , Schworer   AP. , et al. , Donor leucocytes infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantations. . Blood . 1992; ;79: : 1379– 1381 .
    [Google Scholar]
  25. 25. Hebart   H., , Einfele   H. . Diagnosis and treatments of cytomegalovirus infection. . Current Opin. Hematol . 1998; ;5: : 483– 487 .
    [Google Scholar]
  26. 26. De Marie   S. . New developments in the diagnosis and management of invasive fungal infections. . Hematologica . 2000; ;85: : 88– 93 .
    [Google Scholar]
  27. 27. Johnson   PWM., , Simnett   SJ., , Sweetenham   JW., , Morgan   GJ., , Stewart   LA. . Bone marrow and peripheral blood SCT for malignancy. . Health Techn Assess . 1998; ;2: : 1– 187 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2007.2.7
Loading
  • Article Type: Review Article
Keyword(s): GHD , HSCT , RICT and HLA and TRM
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error